Characterizing the subjective, psychomotor, and physiological effects of oral propoxyphene in non-drug-abusing volunteers

Add time:08/18/2019    Source:sciencedirect.com

Background: The subjective, psychomotor, and physiological effects of a widely prescribed prescription opioid, propoxyphene, have not been studied in a population of non-drug-abusing people. The drug also has potential for abuse and it was of interest in the present study to determine if the drug had any abuse liability-related subjective effects in this population. Methods: Eighteen volunteers participated in a crossover, randomized, double-blind study in which they received, all p.o., placebo; 50 mg propoxyphene napsylate; 100 mg propoxyphene napsylate; 200 mg propoxyphene napsylate; 40 mg morphine sulfate; and 2 mg lorazepam. Measures were assessed before and for 300 min after drug administration. Results: Both morphine and lorazepam produced subjective effects. There were no statistically significant subjective effects obtained with any dose of propoxyphene in the group as a whole, but approximately 30–50% of the subjects did appear to experience subjective effects from the drug. Drug liking was not consistently observed in this subset. Propoxyphene, unlike lorazepam, did not impair psychomotor or cognitive performance. Both propoxyphene and morphine produced miosis. Conclusions: There was a lack of statistically significant subjective effects of propoxyphene in the group as a whole, including a propoxyphene dose that was twice as high as the typical clinically-prescribed dose of 100 mg. However, there were some subjects who did report effects, consistent with the notion that patients differ in their sensitivity to opioid effects.

We also recommend Trading Suppliers and Manufacturers of PROPOXYPHENE NAPSYLATE (cas 17140-78-2). Pls Click Website Link as below: cas 17140-78-2 suppliers

Prev:PROPOXYPHENE NAPSYLATE (cas 17140-78-2) maintenance treatment for narcotic dependence: A non-methadone model
Next:The effectiveness and side-effect liability of propoxyphene hydrochloride and PROPOXYPHENE NAPSYLATE (cas 17140-78-2) in patients with postpartum uterine cramping)